Insider Cluster (2 insiders) ·Filed Aug 5, 2026

PCVX

Vaxcyte, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed1mo ago
Insider cluster: 2 insiders, $395K total
Actionable Insight • Neutral

This insider cluster is too small to warrant a trading signal. Monitor for any larger, unplanned open-market sales from C-suite executives, which would be more informative. The company's next pipeline catalyst (likely VAX-24 Phase 3 data) remains the primary driver for the stock.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
PCVX ▲ +10.12% at T+20d
NEUTRAL call ✓ call won +10.12% · α vs SPY +10.72% · entry $55.92 → $61.58
Next anchor: T+60d in 26d
Latest observation: T+38 +4.92% FF3 residual α
Entry anchored
Aug 4, 04:17 PM ET
via 1-min bar
T+1d
+5.31%
call +5.31% · α +5.47%
$58.89
settled 8w ago
T+5d
+6.67%
call +6.67% · α +6.32%
$59.65
settled 7w ago
T+20d
+10.12%
call +10.12% · α +10.72%
$61.58
settled 4w ago
T+60d
—
call — · α —
—
in 26d

Price Chart

Loading chart...

Executive Summary

Two top executives at Vaxcyte — the CEO and CFO — sold a combined $395K in open-market stock over a one-week window, with the CFO's sale following a derivative exercise. The total dollar value is only ~0.005% of the $8.1B market cap, making this a routine, immaterial cluster. No insider buying occurred, and the sales are consistent with standard post-vesting diversification, not a bearish signal on the company's pipeline or prospects.

Key Financial Metrics

Direction
selling
Total Value
$395.0K
Insiders
2

Key Facts

  • CEO Grant Pickering sold 378 shares for ~$21K on 2026-07-27.
  • CFO Andrew Guggenhime sold ~10,000 shares total for ~$374K on 2026-08-03, following derivative exercises.
  • Total open-market sales of ~$395K represent ~0.005% of Vaxcyte's $8.1B market cap.
  • No insider purchases were made during the cluster window.
  • The cluster is small in both absolute and relative terms, consistent with routine portfolio management.

Financial Impact

Total insider sales of ~$395K, or ~0.005% of market cap — trivial and non-material.

insider ownership

Risk Factors

  • No bearish signal from this cluster; the stock remains driven by clinical trial outcomes.
  • If future insider selling accelerates beyond routine vesting-related transactions, it could signal reduced confidence.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (17 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-PCVX-1786003639690
13 reports for PCVX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for PCVX — sortable, filterable
TypeNow
Aug 5, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$55.92 $61.58▲ +10.12%▲ +10.72%$56.69 (+1.38%)
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$60.67 $53.53▼ −11.77%▼ −13.10%$56.69 (−6.56%)
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$60.67 $53.53▼ −11.77%▼ −13.10%$56.69 (−6.56%)
Jun 26, 2026
13w ago
144
NEUTRAL ★ 3/10
$57.72 $54.66▼ −5.30%▼ −5.02%$56.69 (−1.78%)
Jun 23, 2026
14w ago
8-K
NEUTRAL ★ 2/10
$53.87 $56.00▲ +3.95%▲ +2.02%$56.69 (+5.23%)
Jun 19, 2026
15w ago
Insider Cluster
NEUTRAL ★ 3/10
$52.11 $56.20▲ +7.85%▲ +8.00%$56.69 (+8.79%)
Jun 2, 2026
17w ago
Press Release
NEUTRAL ★ 4/10
$46.93 $58.39▲ +24.42%▲ +25.42%$56.69 (+20.80%)
May 6, 2026
21w ago
8-K
BEARISH ★ 7/10
$51.48 $46.93▲ +8.84%▲ +11.97%$56.69 (−10.12%)
Apr 23, 2026
23w ago
DEFA14A
NEUTRAL ★ 3/10
$59.49 $47.39▼ −20.34%▼ −24.37%$56.69 (−4.71%)
Apr 1, 2026
26w ago
Insider Cluster
NEUTRAL ★ 3/10
$58.50 $57.32▼ −2.02%▼ −11.74%$56.69 (−3.09%)
Showing 10 of 13

US Market Status

Market Open — Closes in 3h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Aug 6, 2026